


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-6. (Cancelled)

7. (Currently Amended) ~~The A~~ compound of Claim 4 wherein of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R¹ is -OR⁷;

R² is -R⁸-OR⁷;

R³ is -R¹⁰-N(R⁷)₂;

R^{4a} and R^{4b} are each independently selected from hydrogen, alkynyl or alkynyl;

or R^{4a} is hydrogen, alkynyl or alkynyl and R^{4b} is a direct bond to the carbon at C16;

or R^{4a} and R^{4b} together form alkylidene or haloalkylidene;

R⁵ is alkyl or R⁵ is a direct bond to the carbon at C14;

R⁶ is hydrogen, -R⁸-OR⁷ or -R⁸-N(R⁷)₂;

each R⁷ is independently selected from the group consisting of hydrogen, -R¹⁰-OR⁹, -R¹⁰-N(R⁹)₂, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R⁸ is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R⁹ is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R¹⁰ is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

8. (Currently Amended) The compound of Claim 7 selected from the group consisting of the following:

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-ethylideneoctahydroindene, ammonium chloride salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium chloride salt;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-aminoethyl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-aminoethyl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-difluoromethyleneoctahydroindene;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-difluoromethyleneoctahydroindene, ammonium chloride salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-dichloromethyleneoctahydroindene, ammonium chloride salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1 β -(prepen-2-yl)octahydroindene;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1 β -(propen-2-yl)octahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 α ,5 α -dihydroxy-2 β -hydroxymethylcyclohexyl)-4 α -aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(4-dimethylaminobut-2Z-en-1-yl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(4-dimethylaminobut-2Z-en-1-yl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(ethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(benzyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(cyclopropylmethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(dimethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(dimethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(methyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(methyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(2-methylpropyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(2-methylpropyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(1-methylpiperidin-4-yl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium diacetate salt;


5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(3-nitrobenzyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(piperonyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;

5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(pyrrol-2-ylmethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(furfuryl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-4 β -hydroxy-2 β -hydroxymethylcyclohexyl)-4 α -(pyridin-3-ylmethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-methylpropyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(pyridin-3-ylmethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-hydroxyethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(furfuryl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-dimethylaminoethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-cyclohex-1-en-1-ylethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-morpholin-4-ylethyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene, ammonium acetate salt;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(3-methylphenyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene;
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(benzyl)aminomethyl-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene; and
5-(1 β -methyl-2 β ,4 β -dihydroxycyclohexyl)-4 α -(2-(3-methylphenyl)aminoethyl)-7 $\alpha\beta$ -methyl-1-methyleneoctahydroindene.

9.-21 (Cancelled)

22. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R¹ is -OR⁷;

R² is -R⁸-OR⁷;

R³ is -R¹⁰-N(R⁷)₂;

R^{4a} and R^{4b} together form alkylidene or haloalkylidene;

R⁵ is alkyl;

R⁶ is hydrogen, -R⁸-OR⁷ or -R⁸-N(R⁷)₂;

each R⁷ is independently selected from the group consisting of hydrogen, -R¹⁰-OR⁹, -R¹⁰-N(R⁹)₂, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;


each R⁸ is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R⁹ is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R¹⁰ is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof compound of Claim (1);



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;
 C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl, $-R^6-OR^7$, or $-R^8-N(R^7)_{2t}$, provided that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl, $-R^6-OR^7$, or $-R^8-N(R^7)_{2t}$;

R^4 is $-OR^7$ or $-N(R^7)_{2t}$;

R^2 and R^3 are each independently selected from the group consisting of $-R^6-OR^7$, $-R^9-OC(O)R^9$, $-R^{10}-N(R^7)_{2t}$, $-R^{10}-N(R^9)C(O)R^9$, $-R^{10}-N(R^9)S(O)_tR^9$ (where t is 1 or 2), $-R^{10}-N(R^9)C(NR^9)N(R^7)_{2t}$, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R^{4a} and R^{4b} are each independently selected from hydrogen, alkenyl or alkynyl;

or R^{4a} is hydrogen, alkenyl or alkynyl and R^{4b} is a direct bond to the carbon at C16;

or R^{4a} and R^{4b} together form alkylidene or haloalkylidene;

R^5 is alkyl or R^5 is a direct bond to the carbon at C14;

R^6 is hydrogen, $-R^6-OR^7$ or $-R^8-N(R^7)_{2t}$;

each R^7 is independently selected from the group consisting of hydrogen, $-R^{10}-OR^9$, $-R^{10}-N(R^9)_{2t}$, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;

each R^8 is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R^9 is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and


each R^{10} is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

23. (Cancelled)

24. (Withdrawn and Currently Amended) A method of treating an inflammatory condition or disease in a mammal, which method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound having the following formula (Ia):



wherein:

the A, C or D ring is independently fully saturated;

C1, C4, C11, C12, C15 and C16 are each independently substituted with two hydrogens;

C9 and C14 are each independently substituted with hydrogen;

R^1 is $-OR^7$;

R^2 is $-R^8-OR^7$;

R^3 is $-R^{10}-N(R^7)_2$;

R^{4a} and R^{4b} together form alkylidene or haloalkylidene;

R^5 is alkyl;

R^6 is hydrogen, $-R^8-OR^7$ or $-R^8-N(R^7)_2$;

each R^7 is independently selected from the group consisting of hydrogen, $-R^{10}-OR^9$, $-R^{10}-N(R^9)_2$, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;


each R^8 is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R^9 is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R^{10} is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain,

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof compound of formula (I);



wherein:

the A, C or D ring is independently fully saturated, partially saturated or fully unsaturated;
 C1, C4, C11, C12, C15 and C16 are each independently substituted with two of the following, which are independently selected: hydrogen, alkyl, $-R^8-OR^7$, or $-R^8-N(R^7)_{21}$, provided that C4 is not substituted by two methyl groups;

C9 and C14 are each independently substituted with hydrogen, alkyl, $-R^8-OR^7$, or $-R^8-N(R^7)_{21}$;

R^1 is $-OR^7$ or $-N(R^7)_{21}$;

R^2 and R^3 are each independently selected from the group consisting of $-R^8-OR^7$, $-R^8-OC(O)R^9$, $-R^{10}-N(R^7)_{21}$, $-R^{10}-N(R^9)C(O)R^9$, $-R^{10}-N(R^9)S(O)_tR^9$ (where t is 1 or 2), $-R^{10}-N(R^9)C(NR^9)N(R^9)_{21}$, alkyl, alkenyl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkenyl;

R^{4a} and R^{4b} are each independently selected from hydrogen, alkenyl or alkynyl;

or R^{4a} is hydrogen, alkenyl or alkynyl and R^{4b} is a direct bond to the carbon at C16;

or R^{4a} and R^{4b} together form alkylidene or haloalkylidene;

R^6 is alkyl or R^6 is a direct bond to the carbon at C14;

R^6 is hydrogen, $-R^8-OR^7$ or $-R^8-N(R^7)_{2n}$;

each R^7 is independently selected from the group consisting of hydrogen, $-R^{10}-OR^9$, $-R^{10}-N(R^9)_{2n}$, alkyl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylalkyl, optionally-substituted aryl, optionally-substituted aralkyl, optionally-substituted heterocyclylalkyl, optionally-substituted heteroaryl and optionally-substituted heteroarylalkyl;

each R^8 is independently selected from the group consisting of a direct bond, a straight or branched alkylene chain, and a straight or branched alkenylene chain;

each R^9 is independently selected from the group consisting of hydrogen, alkyl, aryl and aralkyl; and

each R^{10} is independently selected from the group consisting of a straight or branched alkylene and a straight or branched alkenylene chain;

as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

25. (Cancelled)

26. (Withdrawn and Currently Amended) The method of Claim 24 or ~~Claim 25~~ wherein the inflammatory condition or disease is selected from the group consisting of the following:

arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, osteoarthritis, gout, and synovitis), inflammations of the brain (including multiple sclerosis, Alzheimer's, AIDS dementia, stroke, encephalitis, trauma, and Creutzfeld-Jakob disease), inflammatory bowel disease (including Crohn's disease and ulcerative colitis), irritable bowel syndrome, ischemia-reperfusion injury (including myocardial infarction), sarcoidosis, psoriasis, tissue/organ transplant, graft vs host disease, systemic lupus erythematosus, Type I juvenile diabetes, vasculitis, atherosclerosis, cardiomyopathy, autoimmune myocarditis, atopic dermatitis, asthma, allergy, allergic rhinitis, and chronic obstructive pulmonary disease (including emphysema and bronchitis).

27.-29. (Cancelled)